Clinical efficacy of vitamin B1 in ICU-acquired weakness patients.
10.3760/cma.j.cn121430-20240715-00596
- Author:
Dandan ZHOU
1
;
Jianhua GUO
;
Xuebin WANG
Author Information
1. Department of Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai 200120, China. Corresponding author: Wang Xuebin, Email: 1400094@tongji.edu.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Intensive Care Units;
Retrospective Studies;
APACHE;
Muscle Weakness/drug therapy*;
Respiration, Artificial;
Thiamine/therapeutic use*;
C-Reactive Protein;
Interleukin-6/blood*;
Length of Stay;
Male;
Female;
Treatment Outcome;
Propensity Score;
Middle Aged
- From:
Chinese Critical Care Medicine
2024;36(12):1301-1304
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy of vitamin B1 in patients with ICU-acquired weakness (ICU-AW).
METHODS:A retrospective analysis was conducted to select ICU-AW patients treated with vitamin B1 in the intensive care unit (ICU) of Shanghai East Hospital, Tongji University from July 2022 to December 2023. Propensity score matching was used to match the control group and observation group at a 1 : 1 ratio, considering differences in patient age, gender, and acute physiology and chronic health evaluation II (APACHE II). The control group received conventional treatment, while the observation group received vitamin B1 in addition to conventional treatment. Comparisons were made between the two groups in terms of basic information, APACHE II scores, Medical Research Council muscle strength score (MRC), interleukin-6 (IL-6), C-reactive protein (CRP), and serum creatinine (SCr) levels before and after treatment, mechanical ventilation time, and length of ICU stay were collected and compared between the two groups.
RESULTS:A total of 30 patients with ICU-AW were included, both 15 in each group. There were no significant differences in gender, age and APACHE II score between the two groups. There were no significant differences in APACHE II score, MRC score, IL-6, CRP, SCr levels, and the duration of ventilator-assisted ventilation and ICU stay between the two groups of patients before treatment. Both groups showed improvements in APACHE II scores and MRC scores after treatment, with the observation group showing significantly greater improvement compared to the control group (APACHE II score: 10.80±1.47 vs. 12.20±1.52, MRC score: 50.40±7.10 vs. 42.00±8.78, both P < 0.05). After treatment, both groups showed significant reductions in IL-6, CRP, and SCr levels, but there were no significant differences between the observation group and control group. The observation group had significantly shorter durations of mechanical ventilation (days: 7.67±1.54 vs. 9.67±2.44, P < 0.05) and ICU stay (days: 13.33±1.72 vs. 15.13±2.56, P < 0.05) compared to the control group.
CONCLUSIONS:The use of vitamin B1 during the treatment of ICU-AW significantly improves muscle strength and reduces the duration of mechanical ventilation and ICU stay.
